Skip to main content

Cellectis S.A. (CLLS)

NASDAQ: CLLS · Delayed Price · USD
13.41 -0.40 (-2.90%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap618.02M
Revenue (ttm)81.61M
Net Income (ttm)-143.62M
Shares Out45.46M
EPS (ttm)-2.78
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume90,126
Open13.70
Previous Close13.81
Day's Range13.22 - 13.93
52-Week Range11.88 - 34.71
Beta2.21
AnalystsBuy
Price Target34.00 (+153.5%)
Est. Earnings DateNov 4, 2021

About CLLS

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 ...

IndustryBiotechnology
IPO DateFeb 7, 2007
CEOAndre Choulika
Employees272
Stock ExchangeNASDAQ
Ticker SymbolCLLS
Full Company Profile

Financial Performance

In 2020, Cellectis's revenue was 82.46 million, an increase of 258.66% compared to the previous year's 22.99 million. Losses were -81.07 million, -20.59% less than in 2019.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 9 analysts, the average rating for Cellectis stock is "Buy." The 12-month stock price forecast is 34.00, which is an increase of 153.54% from the latest price.

Price Target
$34.00
(153.54% upside)
Analyst Consensus: Buy

News

7 Gene Editing Stocks Promising to Change our DNA

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared fi...

1 week ago - InvestorPlace

Cellectis Announces Participation in Five Investor Conferences

NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using all...

4 weeks ago - GlobeNewsWire

Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021

• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed orrefractory multiple myeloma patients.

1 month ago - GlobeNewsWire

Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le ...

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ : CLLS – EURONEXT GROWTH : ALCLS) (la « Société »), une société d'édition du génome spécialisée dans les essais en immuno-oncologie en ...

1 month ago - GlobeNewsWire

Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using all...

1 month ago - GlobeNewsWire

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest Sci...

2 months ago - InvestorPlace

Cellectis Unveils Four Additional Preclinical Candidates For Solid Tumors

Cellectis SA (NASDAQ: CLLS) has announced four new preclinical UCART product candidates targeting solid tumors - UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, an...

3 months ago - Benzinga

Cellectis' Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufact...

• Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting  B-cell malignancies, and three additional product candidates fo...

3 months ago - GlobeNewsWire

Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 1, 2021

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders' General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France.

3 months ago - GlobeNewsWire

Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-c...

4 months ago - GlobeNewsWire

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies t...

4 months ago - GlobeNewsWire

Alphabet, Aurora Cannabis, NXP Semiconductors and More Wednesday Afternoon Analyst Calls

With the trading day about halfway over, the broader markets were somewhat mixed. The S&P 500 briefly hit an all-time high and quickly pulled back just after the open.

4 months ago - 24/7 Wall Street

Cellectis' Annual Shareholders' General Meeting to be Held on June 1, 2021

NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS).

4 months ago - GlobeNewsWire

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

5 months ago - GlobeNewsWire

Cellectis Completes Sale of $47 million through its ATM program

NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies...

5 months ago - GlobeNewsWire

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Other symbols:BEAMCRSPEDITNTLA
5 months ago - InvestorPlace

Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq

NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies...

5 months ago - GlobeNewsWire

Cellectis: Q4 Earnings Insights

Shares of Cellectis (NASDAQ:CLLS) were flatin after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 20.55% year over year to ($0.88), which missed the est...

6 months ago - Benzinga

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-e...

6 months ago - GlobeNewsWire

Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited alloge...

7 months ago - GlobeNewsWire

Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have entered into a strategic research and development collaboration to develop TALEN gene-edited induced pluripotent stem cells (iPSC) Natural K...

7 months ago - Benzinga

Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells

CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeri...

7 months ago - GlobeNewsWire

Cellectis: Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

7 months ago - GlobeNewsWire

7 CRISPR Stocks for the Future of Medicine

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on In...

8 months ago - InvestorPlace

Cellectis (CLLS) Jumps: Stock Rises 9%

Cellectis (CLLS) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

9 months ago - Zacks Investment Research